サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1682229

造影剤とインジェクターシステムの世界市場：分析と予測、2025年～2035年

Global Contrast Media Agent and Injector Systems Market: Analysis and Forecast, 2025-2035

出版日
発行
BIS Research
ページ情報
英文 120 Pages
納期
1～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
造影剤とインジェクターシステムの世界市場：分析と予測、2025年～2035年
出版日: 2025年03月20日
発行: BIS Research
ページ情報: 英文 120 Pages
納期: 1～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の造影剤とインジェクターシステム市場は、CTスキャン、MRI、X線、超音波検査などの処置中に体内構造をより鮮明に可視化する、現代の画像診断に不可欠な市場です。

造影剤は、画像の鮮明度を向上させるために体内に注入される特殊な物質であり、ヘルスケア専門家がより効果的に異常を検出できるようにします。造影剤の使用は、様々な画像診断技術にとって極めて重要であり、詳細かつ正確な診断を保証します。ヘルスケアニーズが世界的に高まるにつれ、画像技術の進歩も相まって、造影剤とその送達システムに対する需要が高まり、臨床現場における造影剤の重要性が確固たるものとなっています。

世界の造影剤とインジェクターシステム市場を牽引している要因はいくつかあります。第一に、がん、心血管疾患、神経疾患などの慢性疾患の有病率の上昇加が、最適な結果を得るために造影剤を必要とする高度なイメージング技術の需要を高めています。世界保健機関（WHO）によると、がんだけでも毎年数100百万人が死亡しており、造影剤の使用に大きく依存する早期発見の必要性が強調されています。第二に、3T MRIや4D CTスキャンのような画像技術の絶え間ない進歩は、より鮮明で詳細な画像を提供するために、より洗練された高品質の造影剤の使用を必要とします。第三に、世界人口の高齢化により画像診断の頻度が増加し、効果的な造影剤の必要性がさらに高まっています。最後に、診断精度の向上と疾患の早期発見に対する需要の高まりが、造影剤をヘルスケアシステムに不可欠なものにしています。

大きな成長促進要因にもかかわらず、造影剤とインジェクターシステム市場はいくつかの課題に直面しています。主な懸念は、アレルギー反応や腎毒性を含む造影剤による副作用の可能性です。このような安全性への懸念は、特に既往症のある患者において、特定の造影剤の使用を制限する可能性があり、その結果、市場での採用が制限されることになります。さらに、造影剤とそれに伴う画像診断のコストが高いことが、特にヘルスケア予算が限られている中低所得国では障壁となります。また、新しい造影剤と注入システムの承認取得には時間とコストがかかるため、市場への導入が遅れるという規制上の課題もあります。

造影剤と注入器システム市場には多くの機会があります。アジア太平洋やアフリカの一部などの新興市場では医療インフラが拡大しており、これらの地域では画像診断へのアクセスが拡大するため、造影剤の需要が高まると予想されます。さらに、個々の患者に合わせた治療に重点を置く精密医療の台頭が、正確な診断結果を提供できるより専門的な造影剤への需要を押し上げています。造影剤がより高い精度を提供するために分子レベルで設計されるナノテクノロジーと、イメージングシステムを変革する人工知能（AI）の革新は、市場にエキサイティングな機会をもたらしています。ナノ粒子ベースの造影剤は、スキャンの高感度と高解像度を可能にすることでイメージング技術に革命をもたらし、ヘルスケア専門家に新たな道を開くと期待されています。

当レポートでは、世界の造影剤とインジェクターシステム市場について調査し、市場の概要とともに、製品別、用途別、エンドユーザー別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

第1章 世界の造影剤とインジェクターシステム市場概要

  • 市場見通し
  • 業界展望
  • 市場力学

第2章 世界の造影剤とインジェクターシステム市場規模分析（米ドル）2024年～2035年、製品タイプ別

  • 市場概要
  • 成長株市場
  • 造影剤
  • インジェクターシステム

第3章 世界の造影剤とインジェクターシステム市場規模分析（米ドル）2024年～2035年、用途別

  • 市場概要
  • 成長株市場
  • 放射線科
  • 心臓病科
  • 腫瘍科
  • 神経科
  • その他（泌尿器科、消化器科など）

第4章 世界の造影剤とインジェクターシステム市場規模分析（米ドル）2024年～2035年、エンドユーザー別

  • 市場概要
  • 成長株市場
  • 病院
  • 画像診断センター
  • その他（ASC、調査機関等）

第5章 世界の造影剤とインジェクターシステム市場規模分析（米ドル）2024年～2035年、地域別

  • 市場概要

第6章 世界の造影剤とインジェクターシステム市場-競合ベンチマーキングと企業プロファイル

  • 競合ベンチマーキング
  • 競合情勢
    • 各社の主な戦略と展開
    • 主な発展分析
    • 市場シェア分析、2024年
  • 企業プロファイル
    • Bayer AG
    • Beijing Beilu Pharmaceutical Co. Ltd.
    • Bracco Group
    • Fresenius SE & Co. KGaA
    • FUJIFILM Holdings Corporation
    • General Electric Company
    • Guerbet
    • Jiangsu Hengrui Pharmaceutical Co., Ltd
    • Jodas Expoim Pvt. Ltd
    • Lantheus Holdings, Inc.
    • Shenzen Seacrown Electromechanical Co., Ltd
    • Sino Medical-Device Technology Co., Ltd
    • ulrich GmbH & Co. KG
    • Unijules Life Sciences Ltd
    • その他の主要企業
目次
Product Code: BHR1401SB

Global Contrast Media Agent and Injector System Market Industry Overview

The global contrast media agent and injector system market is integral to modern diagnostic imaging, providing enhanced visualization of internal body structures during procedures like CT scans, MRIs, X-rays, and ultrasounds. Contrast media agents are specialized substances injected into the body to improve the clarity of images, allowing healthcare professionals to detect abnormalities more effectively. The use of contrast media agents is crucial for a variety of imaging techniques, ensuring detailed and accurate diagnostics. As healthcare needs increase globally, coupled with advancements in imaging technology, the demand for contrast media agents and their delivery systems is rising, solidifying their importance in clinical practice.

Several factors are driving the global contrast media agent and injector system market. First, the growing prevalence of chronic diseases, such as cancer, cardiovascular disease, and neurological disorders, has elevated the demand for advanced imaging technologies that require contrast media agents for optimal results. According to the World Health Organization (WHO), cancer alone accounts for millions of deaths each year, emphasizing the need for early detection, which heavily relies on the use of contrast media agents. Second, continuous advancements in imaging technologies, such as 3T MRIs and 4D CT scans, necessitate the use of more sophisticated and higher-quality contrast media agents to deliver clearer, more detailed images. Third, the aging global population is leading to an increased frequency of diagnostic imaging procedures, further boosting the need for effective contrast media agents. Lastly, the rising demand for greater diagnostic accuracy and early disease detection is making contrast media agents indispensable in the healthcare system.

Despite the substantial growth drivers, the contrast media agent and injector system market for contrast media agents faces several challenges. A major concern is the potential for adverse reactions to contrast media agents, including allergic reactions or nephrotoxicity. These safety concerns can restrict the use of certain contrast media agents, particularly in patients with pre-existing conditions, which in turn limits their market adoption. Furthermore, the high cost of contrast media agents and the associated imaging procedures can act as a barrier, especially in low- and middle-income countries where healthcare budgets are more constrained. Regulatory hurdles also pose challenges, as obtaining approval for new contrast media agents and injector systems can be a lengthy and costly process, delaying their introduction to the market.

The contrast media agent and injector system market presents numerous opportunities. The growing healthcare infrastructure in emerging markets, such as Asia-Pacific and parts of Africa, is expected to boost demand for contrast media agents as these regions expand access to diagnostic imaging. Additionally, the rise of precision medicine, which focuses on tailoring treatments to individual patients, is driving the demand for more specialized contrast media agents that can provide precise diagnostic results. Innovations in nanotechnology, where contrast media agents are designed at the molecular level to offer higher precision, and artificial intelligence (AI), which is transforming imaging systems, present exciting opportunities for the market. Nanoparticle-based contrast media agents are expected to revolutionize imaging techniques by enabling higher sensitivity and resolution in scans, opening new avenues for healthcare professionals.

Global Contrast Media Agent and Injector System Market Lifecycle Stage

The global contrast media agent and injector system market is experiencing significant growth, with multiple collaborations between key market players aimed at combining resources, expanding customer bases, and enhancing marketing efforts. This growth is further supported by continuous research and development focused on creating innovative products. Additionally, many pharmaceutical companies are broadening their operations and becoming more outsourcing-oriented, which is helping to drive the expansion of the contrast media agent and injector system market.

Industry and Technology Overview

Market Segmentation:

Segmentation 1: by Product

  • Contrast Media Agents
  • Injector Systems

The global contrast media agent and injector system market (by product) is expected to be dominated by the contrast media agents segment.

  • Contrast Media Agents (by Modality)
    • X-Ray/CT Scan
    • MRI
    • Ultrasound

The global contrast media agent market (by modality) is expected to be dominated by the X-Ray/CT scan.

  • Contrast Media Agents (by Type of Media Agent)
    • Iodine-Based Contrast Media Agent
    • Gadolinium-Based Contrast Media Agent
    • Barium-Based Contrast Media Agent
    • Microbubble Contrast Media Agent
    • Others

The global contrast media agent market (by type of media agent) is expected to be dominated by iodine-based contrast media agent.

  • Injector Systems (by Modality)
    • CT Injector Systems
    • MRI Injector Systems
    • Cardiovascular/Angiography Injector Systems

The global contrast media injector system market (by modality) is expected to be dominated by CT injector systems.

  • Injector Systems (by Product)
    • Injector
    • Consumables and Accessories

The global contrast media injector system market (by product) is expected to be dominated by consumables and accessories.

  • Injector Systems (by Injector Type)
    • Single-Head Injectors
    • Dual-Head Injectors
    • Syringeless Injectors

The global contrast media injector system market (by injector type) is expected to be dominated by single-head injectors.

Segmentation 2: by Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest-of-Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest-of-Asia-Pacific
  • Rest-of-the-World

The global contrast media agent and injector system market (by region) is dominated by the North America region.

Recent Developments in Global Contrast Media Agent and Injector System Market

  • In January 2023, Bayer AG received European approval for its iodine-based contrast agents, Ultravist-300 and Ultravist-370, for use in contrast-enhanced mammography (CEM).
  • In December 2022, Beijing Beilu Pharmaceutical Co. Ltd. expanded its operations by establishing a wholly-owned subsidiary in Hong Kong.
  • In April 2022, Beijing Beilu Pharmaceutical Co., Ltd. received the ""Drug Registration Certificate"" from the National Medical Products Administration (NMPA) for its gadobutrol injection.
  • In February 2023, Bracco Group formed a partnership with Wellstar Health System to conduct trials for its FDA-approved VUEWAY (gadopiclenol) injection, a contrast agent designed for MRI applications.
  • In February 2023, Bracco Group acquired all shares of Bracco-Eisai from Eisai and subsequently rebranded the company as Bracco Japan, Ltd.
  • In July 2022, Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA, launched its line of generic contrast media agents in the U.S.
  • In December 2022, General Electric Company partnered with ulrich GmbH & Co. KG to introduce a branded multi-dose contrast media injector in the U.S. market.

Demand - Drivers and Limitations

The following are the drivers for the global contrast media agent and injector system market:

  • Increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector system
  • Upsurge in demand for image-guided diagnostics
  • Growing number of regulatory approvals

The global contrast media agent and injector system market is expected to face some limitations as well due to the following challenges:

  • Rising health concerns post usage of contrast media agents in the body

How can this report add value to an organization?

Growth/Marketing Strategy: The global contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The global contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies have the opportunity to expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals.

Competitive Landscape

The contrast media agent and injector system market is highly competitive, with major players focusing on product innovation and strategic expansion.

Contrast Media Agent And Injector System Key Market Players and Competition Synopsis:

  • Bayer AG
  • Fresenius SE & Co. KGaA
  • FUJIFILM Visualsonics, Inc (Fujifilm Holdings Corporation)
  • General Electric Company
  • Lantheus Medical Imaging
  • Guerbet
  • Bracco Group
  • J.B. Chemicals and Pharmaceuticals Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • ulrich GmbH & Co. KG
  • ShenzenSeacrown Electromechanical Co Ltd
  • Jodas Expoim Pvt. Ltd.
  • Beijing Beilu Pharmaceutical Co. Ltd
  • MEDTRON AG
  • SINO MDT
  • Stanex Drugs & Chemical Pvt. Ltd.
  • Taejoon Pharm
  • Nano Therapeutics Pvt. Ltd.
  • Nemoto Kyorindo Co., Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Contrast Media Agent and Injector Systems Market Overview

  • 1.1 Market Outlook
    • 1.1.1 Definitions
    • 1.1.2 Inclusion and Exclusion Criteria
    • 1.1.3 Market Size, 2024 - 2035 (US$)
    • 1.1.4 Market Growth Scenario
      • 1.1.4.1 Realistic Scenario
      • 1.1.4.2 Optimistic Scenario
      • 1.1.4.3 Pessimistic Scenario
  • 1.2 Industry Outlook
    • 1.2.1 Market Overview
    • 1.2.2 Market Ecosystem
    • 1.2.3 Regulatory Landscape
      • 1.2.3.1 Regulatory and Legal Requirements and Framework in the U.S.
      • 1.2.3.2 Regulatory and Legal Requirements and Framework in Europe
      • 1.2.3.3 Regulatory and Legal Requirements and Framework in Asia-Pacific
      • 1.2.3.4 Regulatory and Legal Requirements and Framework in Other Key Countries
    • 1.2.4 Patent Analysis
      • 1.2.4.1 Patent Filing Trend (by Year)
      • 1.2.4.2 Patent Filing Trend (by Country)
  • 1.3 Market Dynamics
    • 1.3.1 Market Key Trends
    • 1.3.2 Market Drivers
      • 1.3.2.1 Impact Analysis
    • 1.3.3 Market Restraints
      • 1.3.3.1 Impact Analysis
    • 1.3.4 Market Opportunities
      • 1.3.4.1 Impact Analysis

2. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Product Type

  • 2.1 Market Overview
  • 2.2 Growth Share Market
  • 2.3 Contrast Media Agent
    • 2.3.1 By Modality
      • 2.3.1.1 X-Ray/CT scan
      • 2.3.1.2 MRI
      • 2.3.1.3 Ultrasound
    • 2.3.2 By Type of Media Agent
      • 2.3.2.1 Iodine-Based Contrast Media Agent
      • 2.3.2.2 Gadolinium-Based Contrast Media Agent
      • 2.3.2.3 Barium-Based Contrast Media Agent
      • 2.3.2.4 Microbubble Contrast Media Agent
      • 2.3.2.5 Others
  • 2.4 Injector System
    • 2.4.1 By Product
      • 2.4.1.1 Injector
      • 2.4.1.2 Consumable and Accessories
    • 2.4.2 By Modality
      • 2.4.2.1 CT Injector Systems
      • 2.4.2.2 MRI Injector Systems
      • 2.4.2.3 Cardiovascular/Angiography Injector Systems
    • 2.4.3 By Injector Type
      • 2.4.3.1 Single Head Injectors
      • 2.4.3.2 Dual Head Injectors
      • 2.4.3.3 Syringeless Injectors

3. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Application

  • 3.1 Market Overview
  • 3.2 Growth Share Market
  • 3.3 Radiology
  • 3.4 Cardiology
  • 3.5 Oncology
  • 3.6 Neurology
  • 3.7 Others (Urology, Gastroenterology, etc.)

4. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by End User

  • 4.1 Market Overview
  • 4.2 Growth Share Market
  • 4.3 Hospitals
  • 4.4 Diagnostic Imaging Centers
  • 4.5 Others (ASCs, Research Institutes, etc.)

5. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Region

  • 5.1 Market Overview
    • 5.1.1 Market Dynamics
    • 5.1.2 Market Size and Forecast
      • 5.1.2.1 North America Contrast Media Agent and Injector Systems Market
        • 5.1.2.1.1 Key Findings
        • 5.1.2.1.2 Market Dynamics
        • 5.1.2.1.3 Impact Analysis
        • 5.1.2.1.4 Market Sizing and Forecast
          • 5.1.2.1.4.1 North America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.2 North America Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3 North America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.1.4.3.1 U.S.
          • 5.1.2.1.4.3.1.1 U.S. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.1.2 U.S. Contrast Media Injector System Market (by Product)
          • 5.1.2.1.4.3.2 Canada.
          • 5.1.2.1.4.3.2.1 Canada Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.1.4.3.2.2 Canada Contrast Media Injector System Market (by Product)
      • 5.1.2.2 Europe Contrast Media Agent and Injector Systems Market
        • 5.1.2.2.1 Key Findings
        • 5.1.2.2.2 Market Dynamics
        • 5.1.2.2.3 Impact Analysis
        • 5.1.2.2.4 Market Sizing and Forecast
          • 5.1.2.2.4.1 Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.2 Europe Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3 Europe Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.2.4.3.1 U.K.
          • 5.1.2.2.4.3.1.1 U.K. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.1.2 U.K. Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.2 Germany.
          • 5.1.2.2.4.3.2.1 Germany Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.2.2 Germany Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.3 France
          • 5.1.2.2.4.3.3.1 France Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.3.2 France Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.4 Italy
          • 5.1.2.2.4.3.4.1 Italy Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.4.2 Italy Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.5 Spain
          • 5.1.2.2.4.3.5.1 Spain. Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.5.2 Spain Contrast Media Injector System Market (by Product)
          • 5.1.2.2.4.3.6 Rest of Europe.
          • 5.1.2.2.4.3.6.1 Rest of Europe Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.2.4.3.6.2 Rest of Europe Contrast Media Injector System Market (by Product)
      • 5.1.2.3 Asia-Pacific Contrast Media Agent and Injector Systems Market
        • 5.1.2.3.1 Key Findings
        • 5.1.2.3.2 Market Dynamics
        • 5.1.2.3.3 Impact Analysis
        • 5.1.2.3.4 Market Sizing and Forecast
          • 5.1.2.3.4.1 Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.2 Asia-Pacific Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3 Asia-Pacific Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.3.4.3.1 China
          • 5.1.2.3.4.3.1.1 China Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.1.2 China Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.2 Japan
          • 5.1.2.3.4.3.2.1 Japan Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.2.2 Japan Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.3 India
          • 5.1.2.3.4.3.3.1 India Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.3.2 India Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.4 Australia
          • 5.1.2.3.4.3.4.1 Australia Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.4.2 Australia Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.5 South Korea
          • 5.1.2.3.4.3.5.1 South Korea Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.5.2 South Korea Contrast Media Injector System Market (by Product)
          • 5.1.2.3.4.3.6 Rest-of- Asia-Pacific
          • 5.1.2.3.4.3.6.1 Rest-of-Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.3.4.3.6.2 Rest-of-Asia-Pacific Contrast Media Injector System Market (by Product)
      • 5.1.2.4 Latin America Contrast Media Agent and Injector Systems Market
        • 5.1.2.4.1 Key Findings
        • 5.1.2.4.2 Market Dynamics
        • 5.1.2.4.3 Impact Analysis
        • 5.1.2.4.4 Market Sizing and Forecast
          • 5.1.2.4.4.1 Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.2 Latin America Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3 Latin America Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.4.4.3.1 Brazil
          • 5.1.2.4.4.3.1.1 Brazil Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.1.2 Brazil Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.2 Mexico
          • 5.1.2.4.4.3.2.1 Mexico Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.2.2 Mexico Contrast Media Injector System Market (by Product)
          • 5.1.2.4.4.3.3 Rest-of-Latin America
          • 5.1.2.4.4.3.3.1 Rest-of-Latin America Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.4.4.3.3.2 Rest-of-Latin America Contrast Media Injector System Market (by Product)
      • 5.1.2.5 Middle East and Africa Contrast Media Agent and Injector Systems Market
        • 5.1.2.5.1 Key Findings
        • 5.1.2.5.2 Market Dynamics
        • 5.1.2.5.3 Impact Analysis
        • 5.1.2.5.4 Market Sizing and Forecast
          • 5.1.2.5.4.1 Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.2 Middle East and Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3 Middle East and Africa Contrast Media Agent and Injector System Market (by Country)
          • 5.1.2.5.4.3.1 UAE
          • 5.1.2.5.4.3.1.1 UAE Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.1.2 UAE Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.2 South Africa
          • 5.1.2.5.4.3.2.1 South Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.2.2 South Africa Contrast Media Injector System Market (by Product)
          • 5.1.2.5.4.3.3 Rest-of-MEA
          • 5.1.2.5.4.3.3.1 Rest-of-Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
          • 5.1.2.5.4.3.3.2 Rest-of-Middle East and Africa Contrast Media Injector System Market (by Product)

6. Global Contrast Media Agent and Injector Systems Market- Competitive Benchmarking and Company Profiles

  • 6.1 Competitive Benchmarking
  • 6.2 Competitive Landscape
    • 6.2.1 Key Strategies and Developments by Company
      • 6.2.1.1 Funding Activities
      • 6.2.1.2 Mergers and Acquisitions
      • 6.2.1.3 Regulatory Approvals
      • 6.2.1.4 Partnerships, Collaborations, and Business Expansions
    • 6.2.2 Key Developments Analysis
    • 6.2.3 Market Share Analysis, 2024
  • 6.3 Company Profiles
    • 6.3.1 Bayer AG
      • 6.3.1.1 Company Overview
      • 6.3.1.2 Product Portfolio/Offering
      • 6.3.1.3 Key Competitors
      • 6.3.1.4 Analyst View
    • 6.3.2 Beijing Beilu Pharmaceutical Co. Ltd.
      • 6.3.2.1 Company Overview
      • 6.3.2.2 Product Portfolio/Offering
      • 6.3.2.3 Key Competitors
      • 6.3.2.4 Analyst View
    • 6.3.3 Bracco Group
      • 6.3.3.1 Company Overview
      • 6.3.3.2 Product Portfolio/Offering
      • 6.3.3.3 Key Competitors
      • 6.3.3.4 Analyst View
    • 6.3.4 Fresenius SE & Co. KGaA
      • 6.3.4.1 Company Overview
      • 6.3.4.2 Product Portfolio/Offering
      • 6.3.4.3 Key Competitors
      • 6.3.4.4 Analyst View
    • 6.3.5 FUJIFILM Holdings Corporation
      • 6.3.5.1 Company Overview
      • 6.3.5.2 Product Portfolio/Offering
      • 6.3.5.3 Key Competitors
      • 6.3.5.4 Analyst View
    • 6.3.6 General Electric Company
      • 6.3.6.1 Company Overview
      • 6.3.6.2 Product Portfolio/Offering
      • 6.3.6.3 Key Competitors
      • 6.3.6.4 Analyst View
    • 6.3.7 Guerbet
      • 6.3.7.1 Company Overview
      • 6.3.7.2 Product Portfolio/Offering
      • 6.3.7.3 Key Competitors
      • 6.3.7.4 Analyst View
    • 6.3.8 Jiangsu Hengrui Pharmaceutical Co., Ltd
      • 6.3.8.1 Company Overview
      • 6.3.8.2 Product Portfolio/Offering
      • 6.3.8.3 Key Competitors
      • 6.3.8.4 Analyst View
    • 6.3.9 Jodas Expoim Pvt. Ltd
      • 6.3.9.1 Company Overview
      • 6.3.9.2 Product Portfolio/Offering
      • 6.3.9.3 Key Competitors
      • 6.3.9.4 Analyst View
    • 6.3.10 Lantheus Holdings, Inc.
      • 6.3.10.1 Company Overview
      • 6.3.10.2 Product Portfolio/Offering
      • 6.3.10.3 Key Competitors
      • 6.3.10.4 Analyst View
    • 6.3.11 Shenzen Seacrown Electromechanical Co., Ltd
      • 6.3.11.1 Company Overview
      • 6.3.11.2 Product Portfolio/Offering
      • 6.3.11.3 Key Competitors
      • 6.3.11.4 Analyst View
    • 6.3.12 Sino Medical-Device Technology Co., Ltd
      • 6.3.12.1 Company Overview
      • 6.3.12.2 Product Portfolio/Offering
      • 6.3.12.3 Key Competitors
      • 6.3.12.4 Analyst View
    • 6.3.13 ulrich GmbH & Co. KG
      • 6.3.13.1 Company Overview
      • 6.3.13.2 Product Portfolio/Offering
      • 6.3.13.3 Key Competitors
      • 6.3.13.4 Analyst View
    • 6.3.14 Unijules Life Sciences Ltd
      • 6.3.14.1 Company Overview
      • 6.3.14.2 Product Portfolio/Offering
      • 6.3.14.3 Key Competitors
      • 6.3.14.4 Analyst View
    • 6.3.15 Other Key Companies